Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase (IC50: 7.5 nM).

HIV-1 integrase:7.5 nM

MT-2 cells are infected in bulk culture with HIV-1 IIIb at a cell density of 2×10^6 cells/mL for 3 h at 37°C. Infected MT-2 cells receive either DMSO (mock-treated control) or Bictegravir at a final concentration greater than or equal to 20 times their respective antiviral EC50. These plates are incubated at 37°C for either 12 h (for late reverse transcription product quantification) or 24 h (for 2-LTR circle and Alu-LTR product quantification), after which time the cells are harvested for total DNA isolation. DNA is extracted from each well using the DNA minikit and collected as a 100-μL eluate. TaqMan real-time PCR-quantified 2-LTR junctions, late reverse transcription products, and integration junctions (Alu-LTR) are normalized to the level of host globin gene in each sample[1].

DMSO: 252.5 mg/mL (561.89 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.45 mM), Sonication is recommended.